OncoSil Medical secures $5.6 million from its three largest institutional backers
OncoSil Medical (ASX: OSL) has received commitments for $5.6 million in new capital from its three largest institutional investors, funding the commercial launch of its OncoSil™ device following recent FDA and TGA approvals. The backers are Pengana High Conviction Equities Fund, Regal Partners and Australian Ethical Investments.
The OncoSil Medical capital raise comprises two components structured to support the device’s commercialisation in the United States and Australia. The company describes the funding as an endorsement of its transition into commercial-stage operations.
The first component is a $4.0 million placement, issued through 4.0 million shares at $1.00 each. That price represents a 9.9% premium to the last closing price on 7 September 2026, and the placement falls within the company’s existing capacity under ASX Listing Rule 7.1.
The second component is an early exercise of listed options. Around 1.8 million OSLOE options were exercised at $0.90, raising approximately $1.6 million. Notably, these options were not due to expire until the end of June 2027.
Allotment and issue of the placement shares, along with shares from the option exercise, is expected to occur on 10 September 2026. Normal trading is expected to commence on 11 September 2026.
When big ASX news breaks, our subscribers know first
Why the raise matters for the investment case
The raise strengthens the company’s balance sheet at a pivotal moment in its transition to commercialisation. On a pro-forma basis, cash and cash equivalents rise to $12.1 million, based on the $5.6 million raised plus $6.5 million in cash held at 30 June 2026.
The involvement of the company’s three largest shareholders carries a signalling element. Participation at a 9.9% premium to the last traded price, combined with the decision to exercise options well ahead of their June 2027 expiry, reflects a level of conviction from existing holders as the business moves towards commercial launch.
Dr Thomas Duthy, Chairman of OncoSil Medical
“We thank our three largest institutional investors for their confidence in our business and outlook. With both FDA and TGA approvals secured this year, this capital will support our transition into commercialisation in the United States and Australia. The placement and early exercise of the listed options by our major holders, which are not due to expire until the end of June 2027, is a strong endorsement of our outlook in FY27 as we move rapidly towards multiple value accretive events for the Company with a strong balance sheet and a committed team.”
| Component | Amount | Price | Detail |
|---|---|---|---|
| Placement | $4.0M | $1.00 | 4.0M shares, 9.9% premium to last close (7 Sep 2026), under Listing Rule 7.1 |
| Option exercise | ~$1.6M | $0.90 | ~1.8M OSLOE options, exercised ahead of June 2027 expiry |
| Total raised | $5.6M | — | Combined new capital committed |
| Pro-forma cash | $12.1M | — | Based on $5.6M raised plus $6.5M cash at 30 June 2026 |
Understanding OncoSil™ and the cancers it targets
OncoSil™ is a single-use brachytherapy (internal radiation) device designed to deliver a pre-determined dose of beta radiation directly into cancerous tissue. It uses Phosphorous-32 (³²P) microparticles placed within the tumour, an approach the company states enables a greater radiation dose to be delivered to the tumour compared with external beam radiotherapy, while sparing surrounding critical organs.
The device carries two distinct indications depending on the market:
-
United States (FDA, Humanitarian Device Exemption): treatment of patients with distal cholangiocarcinoma (dCCA) that is both unresectable (locally advanced and/or unfit for surgery) and non-metastatic, as an adjunct to systemic therapy.
-
Outside the United States: treatment of patients with unresectable locally advanced pancreatic cancer, in addition to gemcitabine-based chemotherapy.
The disease burden underpinning these indications is significant. According to the company, pancreatic cancer is the 12th most common cancer in men and the 11th most common in women globally, with around 500,000 new cases detected each year. It is generally diagnosed at a later stage, giving it a poor prognosis for long-term survival.
Distal cholangiocarcinoma is described as a rare form of bile duct cancer, often diagnosed at an advanced stage when surgery may no longer be possible, and is also associated with a poor prognosis. For investors, this large and underserved patient population frames the potential market opportunity.
OncoSil™ is currently approved for sale in 30+ countries, including the European Union, United Kingdom, United States, Australia, Saudi Arabia, Türkiye and Israel. The device has also been designated a Breakthrough Device in both the United States and Europe.
Path to commercialisation and FY27 milestones
The company entered FY27 having achieved both of its principal regulatory objectives. The Australian TGA granted approval in May 2026 for the treatment of locally advanced pancreatic cancer in addition to gemcitabine-based chemotherapy. The U.S. FDA followed in August 2026, approving the device under the Humanitarian Device Exemption pathway for unresectable, non-metastatic distal cholangiocarcinoma as an adjunct to systemic therapy.
TGA approval in May 2026 made OncoSil the first and only Class III medical device approved in Australia for directly targeting tumours within the pancreas, covering a domestic patient population of approximately 4,353 new pancreatic cancer diagnoses per year.
The FDA approval for distal cholangiocarcinoma arrived on 17 August 2026 under the Humanitarian Device Exemption pathway, designating OncoSil as the first and only Class III device cleared for this indication and opening an addressable U.S. market the company estimates at approximately A$80 million per annum.
These represent the addition of US and Australian market access to a device that already held CE Marking and approvals across more than 30 countries.
According to the company, several milestones are anticipated to be delivered in 1H FY27:
-
Commencement of the G-BA funded study
-
Two additional European regulatory filings, being the PANCOSIL percutaneous label change submission and the TRIPP-FFX FOLFIRINOX label change submission
-
Commencement of manufacturing at the OncoSil Medical/Cyclotek facility (subject to approval)
Additional milestones referenced by the company across FY27 include the OncoSil™ device US label filing to the FDA (HDE), a CMS Transitional Pass Through Payment reimbursement application, ISO 13485 certification for the OncoSil/Cyclotek manufacturing facility, presentation of TRIPP-FFX clinical trial results at the ESMO GI Congress, EU regulatory approvals for the PANCOSIL and TRIPP-FFX label changes, and the commercial launches of OncoSil™ in Australia and the United States.
For investors, these represent multiple near-term catalysts now supported by a strengthened balance sheet.
What comes next
With pro-forma cash of $12.1 million and dual regulatory approvals secured in the United States and Australia, OncoSil Medical enters FY27 funded for its commercial transition. The strengthened position follows direct participation from its three largest institutional holders.
Management has pointed to a catalyst-rich period ahead, spanning further regulatory filings, manufacturing progress and the planned commercial launches. Execution against these milestones will be the key measure of progress as OncoSil commercialisation gets underway.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000 active subscribers already rely on it to stay ahead of market-moving announcements. Click the “Free Alerts” button at StockWire X to ensure the next major healthcare update lands in your inbox the moment it breaks.